(RMD) ResMed - Ratings and Ratios
Medical Devices, Software Applications, Respiratory Care, Sleep Solutions, Cloud
RMD EPS (Earnings per Share)
RMD Revenue
Description: RMD ResMed
ResMed Inc. is a leading healthcare company that develops and markets innovative medical devices and cloud-based software applications for the diagnosis and treatment of respiratory disorders, including sleep apnea.
The companys product portfolio includes a range of diagnostic devices, such as ApneaLink Air and NightOwl, which provide accurate and reliable measurements of sleep patterns and respiratory activity. Additionally, ResMed offers cloud-based solutions like AirView and myAir, which enable remote monitoring and patient engagement, improving treatment compliance and outcomes.
ResMeds software solutions, including Brightree, MatrixCare, and HEALTHCAREfirst, cater to various healthcare providers, such as home medical equipment suppliers, senior living facilities, and hospice organizations, streamlining their operations and improving patient care. The companys out-of-hospital software solutions have a strong presence in the market, with a large customer base.
From a financial perspective, ResMed has demonstrated strong growth and profitability, with a return on equity (ROE) of 25.18%. The companys market capitalization stands at approximately $37.7 billion, with a forward price-to-earnings (P/E) ratio of 24.69. Key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin should be closely monitored to assess the companys future prospects.
Some additional KPIs to consider when evaluating ResMeds performance include: - Revenue growth rate: To assess the companys ability to expand its customer base and increase sales. - Gross margin: To evaluate the companys pricing power and cost management. - Operating margin: To assess the companys ability to maintain profitability. - Debt-to-equity ratio: To evaluate the companys capital structure and financial leverage. - Research and development (R&D) expenses as a percentage of revenue: To assess the companys commitment to innovation and new product development.
RMD Stock Overview
| Market Cap in USD | 40,564m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1995-06-02 |
RMD Stock Ratings
| Growth Rating | 38.8% |
| Fundamental | 93.6% |
| Dividend Rating | 55.5% |
| Return 12m vs S&P 500 | -7.83% |
| Analyst Rating | 3.95 of 5 |
RMD Dividends
| Dividend Yield 12m | 0.85% |
| Yield on Cost 5y | 1.34% |
| Annual Growth 5y | 5.30% |
| Payout Consistency | 100.0% |
| Payout Ratio | 22.9% |
RMD Growth Ratios
| Growth Correlation 3m | 64.7% |
| Growth Correlation 12m | 54.8% |
| Growth Correlation 5y | 20.1% |
| CAGR 5y | 8.76% |
| CAGR/Max DD 3y | 0.20 |
| CAGR/Mean DD 3y | 0.98 |
| Sharpe Ratio 12m | 0.27 |
| Alpha | 0.20 |
| Beta | 0.091 |
| Volatility | 30.56% |
| Current Volume | 831.5k |
| Average Volume 20d | 940.9k |
| Stop Loss | 263.5 (-3%) |
| Signal | -0.93 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (1.40b TTM) > 0 and > 6% of Revenue (6% = 308.8m TTM) |
| FCFTA 0.20 (>2.0%) and ΔFCFTA 1.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 47.72% (prev 31.83%; Δ 15.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.21 (>3.0%) and CFO 1.75b > Net Income 1.40b (YES >=105%, WARN >=100%) |
| Net Debt (-327.1m) to EBITDA (1.92b) ratio: -0.17 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.34 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (147.0m) change vs 12m ago -0.34% (target <= -2.0% for YES) |
| Gross Margin 59.36% (prev 57.92%; Δ 1.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 68.40% (prev 66.15%; Δ 2.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 100.2 (EBITDA TTM 1.92b / Interest Expense TTM 16.8m) >= 6 (WARN >= 3) |
Altman Z'' 8.76
| (A) 0.30 = (Total Current Assets 3.51b - Total Current Liabilities 1.05b) / Total Assets 8.17b |
| (B) 0.74 = Retained Earnings (Balance) 6.08b / Total Assets 8.17b |
| (C) 0.22 = EBIT TTM 1.69b / Avg Total Assets 7.52b |
| (D) 2.72 = Book Value of Equity 6.01b / Total Liabilities 2.21b |
| Total Rating: 8.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 93.58
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 4.14% = 2.07 |
| 3. FCF Margin 32.23% = 7.50 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda 0.38 = 2.39 |
| 6. ROIC - WACC (= 16.62)% = 12.50 |
| 7. RoE 25.51% = 2.13 |
| 8. Rev. Trend 89.19% = 6.69 |
| 9. EPS Trend 96.25% = 4.81 |
What is the price of RMD shares?
Over the past week, the price has changed by +0.46%, over one month by -5.04%, over three months by +8.87% and over the past year by +9.24%.
Is ResMed a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RMD is around 257.51 USD . This means that RMD is currently overvalued and has a potential downside of -5.23%.
Is RMD a buy, sell or hold?
- Strong Buy: 8
- Buy: 4
- Hold: 6
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the RMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 291.9 | 7.4% |
| Analysts Target Price | 291.9 | 7.4% |
| ValueRay Target Price | 281.3 | 3.5% |
Last update: 2025-09-08 04:49
RMD Fundamental Data Overview
CCE Cash And Equivalents = 1.21b USD (last quarter)
P/E Trailing = 29.1632
P/E Forward = 25.974
P/S = 7.8822
P/B = 6.7971
P/EG = 1.8663
Beta = 0.848
Revenue TTM = 5.15b USD
EBIT TTM = 1.69b USD
EBITDA TTM = 1.92b USD
Long Term Debt = 658.4m USD (from longTermDebt, last quarter)
Short Term Debt = 70.9m USD (from shortTermDebt, last quarter)
Debt = 729.3m USD (Calculated: Short Term 70.9m + Long Term 658.4m)
Net Debt = -327.1m USD (from netDebt column, last quarter)
Enterprise Value = 40.08b USD (40.56b + Debt 729.3m - CCE 1.21b)
Interest Coverage Ratio = 100.2 (Ebit TTM 1.69b / Interest Expense TTM 16.8m)
FCF Yield = 4.14% (FCF TTM 1.66b / Enterprise Value 40.08b)
FCF Margin = 32.23% (FCF TTM 1.66b / Revenue TTM 5.15b)
Net Margin = 27.22% (Net Income TTM 1.40b / Revenue TTM 5.15b)
Gross Margin = 59.36% ((Revenue TTM 5.15b - Cost of Revenue TTM 2.09b) / Revenue TTM)
Tobins Q-Ratio = 6.67 (Enterprise Value 40.08b / Book Value Of Equity 6.01b)
Interest Expense / Debt = 0.79% (Interest Expense 5.76m / Debt 729.3m)
Taxrate = 16.50% (276.8m / 1.68b)
NOPAT = 1.41b (EBIT 1.69b * (1 - 16.50%))
Current Ratio = 3.34 (Total Current Assets 3.51b / Total Current Liabilities 1.05b)
Debt / Equity = 0.12 (Debt 729.3m / last Quarter total Stockholder Equity 5.97b)
Debt / EBITDA = 0.38 (Net Debt -327.1m / EBITDA 1.92b)
Debt / FCF = 0.44 (Debt 729.3m / FCF TTM 1.66b)
Total Stockholder Equity = 5.49b (last 4 quarters mean)
RoA = 17.14% (Net Income 1.40b, Total Assets 8.17b )
RoE = 25.51% (Net Income TTM 1.40b / Total Stockholder Equity 5.49b)
RoCE = 27.45% (Ebit 1.69b / (Equity 5.49b + L.T.Debt 658.4m))
RoIC = 22.87% (NOPAT 1.41b / Invested Capital 6.16b)
WACC = 6.25% (E(40.56b)/V(41.29b) * Re(6.35%)) + (D(729.3m)/V(41.29b) * Rd(0.79%) * (1-Tc(0.17)))
Shares Correlation 3-Years: 13.74 | Cagr: -0.00%
Discount Rate = 6.35% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈1.51b ; Y1≈1.86b ; Y5≈3.18b
Fair Price DCF = 369.2 (DCF Value 54.05b / Shares Outstanding 146.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 96.25 | EPS CAGR: 20.99% | SUE: 0.71 | # QB: 0
Revenue Correlation: 89.19 | Revenue CAGR: 13.56% | SUE: 0.0 | # QB: 0
Additional Sources for RMD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle